BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss

Reuters

2025/11/18

<a href="https://laohu8.com/S/BICX">BioCorRx Inc.</a> reports Q3 revenue of $635,224 and reduced net loss

BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584953929"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584953929\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584953929?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584953929","market":"fut","top_or_hot":-1,"title":"BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BICX\">BioCorRx Inc.</a> reports Q3 revenue of $635,224 and reduced net loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BICX\">BioCorRx Inc.</a> reports Q3 revenue of $635,224 and reduced net loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4185","symbol_name":"保健护理机构","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL9zk6n9:1","article_id":"2584953929","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584953929","pubTimestamp":1763475256,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4185":"保健护理机构","BICX":"BioCorRx Inc."},"translate_title":"BioCorRx Inc.报告第三季度收入为635,224美元，净亏损减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BICX":0.9},"content_text":"BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss\n    \n\n        BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}